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Caron M, Emery MP, Perrier LL, Acquadro C, Escanez-Virieux MP 
MAPI Research Trust, Lyon, France  
OBJECTIVES: 1) To identify antidiabetic products approved with a Patient-
Reported Outcome (PRO) labeling claim in Europe and the USA, and 2) to list the 
differences found in Europe versus the USA in terms of products and labeling. 
METHODS: The search was performed on the FDA- and EMA-approved medicinal 
product labels (from 1995 to August 2012 inclusive). The review was conducted 
through a systematic manual review of antidiabetic product labelings. RESULTS: 
A total of 96 antidiabetic products were retrieved: 53 approved by the EMA, 43 by 
the FDA (generics excluded). Only two products with a PRO labeling claim were 
found in Europe (i.e., Insulin Glulisin and Exenatid), and none in the USA. PROs 
identified in both claims were self-monitored blood glucose (SMBG) profiles and 
were used as secondary endpoints. Although Insulin Glulisin and Exenatid were 
also approved by the FDA (on the same studies used in Europe) their US label did 
not mention any results based on SMBG profiles. Reasons for not including them 
in the label were not given in the corresponding medical reviews. However, the 
analysis of other products’ reviews, such as Insulin Aspart or Liraglutide, showed 
a reluctance from reviewers to include results based on SMBG profiles in the 
labels. Reviewers questioned the validity of the glucose profiles based on self-
collected readings because of compliance issues and of a lower degree of 
accuracy of values obtained from glucometers versus lab measures in a clinic. 
Although measured in some cases, other PROs, such as quality of life or 
treatment satisfaction, were never considered for inclusion in labeling with any 
reasons given. CONCLUSIONS: Our review showed that Patient-Reported 
Outcomes are rarely included in antidiabetic product labels in Europe and in the 
US. Other than discussions on the validity of self-monitored blood glucose 
profiles, reasons for such non-inclusion were not provided.  
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OBJECTIVES: To assess diabetes related knowledge among urban poor 
population of Tunku village, Jelutong, Penang, Malaysia. METHODS: A 
questionnaire based, cross-sectional observational study was carried out. All 
residence of the area (age 18 and above) were targeted. The study was conducted 
from September to November 2012. Descriptive statistics were applied to 
summarize the data. All analyses were performed by using Statistical Package for 
Social Sciences (SPSS) software version 17. RESULTS: A total of 104 residents 
agreed to participate in the study. The cohort was dominated by females (n=70, 
67.3%) and ethnic group of Malay (n=71, 68.3%) with mean age of 56.9±13.4 years. 
More than half (n=61, 58.7%) of the respondents were considered as low income 
earners as the monthly household income was less than Ringgit Malaysia 1000. 
Ninety one (87.5%) knew the definition of diabetes whereas (n=77, 74%) had 
knowledge about the normal glucose level in the body). Eight six (82.7%) had the 
knowledge about the complications associated with diabetes. Majority of them 
believed that regular exercise can control diabetes, whereas only 25 (24%) 
believed that diet modification can help in managing the diabetes. Twenty one 
(20.2%) stated that diabetes is a disease of old age. The mean diabetes knowledge 
score was 6.92±2.027 out of 10. CONCLUSIONS: The study revealed that the 
respondent had adequate diabetes related knowledge. However, certain diabetes 
related attributes were lacking in the population. It is advisable that efforts 
should be made to educate the residents of the urban poor areas for adequate 
management of diabetes.  
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OBJECTIVES: The impact of memory problems (MPs) on patient insulin taking 
behavior, functioning, well-being and diabetes management is not well 
understood. The purpose of this study was to examine these impacts in China, 
the country with the largest diabetes population in the world. METHODS: MPs 
were defined as: unintentionally forgetting (UF) to take insulin, questioning 
whether or not insulin had been taken (QT), or questioning how much insulin 
was taken (QD). A web-based survey examining circumstances leading to the MP, 
corrective actions taken, impact on health well-being and diabetes management 
was conducted. RESULTS: A total of 354 respondents (217 or 61.3% Type 1, 137 or 
38.7% Type 2) completed the survey, 59% male, mean age of 43.2 (±13.4, 25-70) 
and mean age of diabetes onset of 36.9 (±12.0, 2-65). The prevalence of MPs was 
high, with 74.6% forgetting, 83.1% questioning whether taken and 65.8% 
questioning how much insulin taken in the past month. MPs occurred most 
frequently at work and the major reasons for the MP were being tired or busy. 
Depending upon MP type, between 16.2% (QD) – 20.5% (UF) of respondents 
skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP and then required between 4.9 (QD)–10.1 (UF) hours to return 
to a normal blood glucose range. Patients conducted between 1.6 (QT/QD) –4.6 
(UF) extra BG monitoring tests and reported a moderate negative impact on their 
physical, emotional and functioning as well as their ability to function at work. 
Further, between 16.2% (QT) and 40.9% (UF) visited their health care provider as a 
result of a MP. Economic implications include cost of additional BG monitoring 
strips, lost work productivity and health care resource utilization. 
CONCLUSIONS: These findings suggest that MPs in China carry financial burden, 
impact patients functioning and well-being and may be serious obstacles to 
optimal diabetes control.  
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OBJECTIVES: To qualitatively examine issues regarding unintentional dosing 
irregularities due to memory issues which may impact insulin taking behavior in 
people with diabetes. METHODS: Seven focus groups and eight individual 
interviews were held (Canada, Germany, China). Respondents were recruited 
who had experienced at least two instances in the previous three months of 
forgetting the insulin dose, time/amount taken, or being unsure if they took their 
insulin. Transcripts were coded thematically, based on grounded theoretical 
approach. RESULTS: Sixty-four people participated: mean age 50.1 (range 18 to 
72), (34% type 1, 66% type 2). Analysis generated 6 domains: behaviors forgotten, 
reasons for forgetting, how they became aware that they had forgotten their 
insulin, consequences of forgetting, corrective actions, and the emotional impact 
of forgetting insulin. Respondents reported forgetting both bolus and basal 
insulin doses and often felt uncertain about if they administered their insulin 
dose, the dose amount or time taken. Major reasons for these memory issues 
were: forgetting due to disruptions in their daily routine, distraction by social 
events, minor interruptions, and being generally busy. They became aware they 
forgot due to their own reminder systems as well as symptoms of hyperglycemia 
and blood glucose testing. People employ a wide variety of strategies and 
corrective actions when they think they have forgotten and often monitor their 
blood glucose more frequently following dosing irregularities. Further, patients 
often question as to whether or not they took their insulin with greater 
frequency than times when they actually forgot and worry about the impact of 
these behaviors on maintaining stable blood glucose control. CONCLUSIONS: 
Unintentional memory issues does impact insulin taking behavior , leads to 
dosing irregularities and contributes to patient uncertainty and worry about their 
diabetes management. Insulin strategies that assist patients in managing 
memory related dosing issues may reduce treatment costs, improve adherence 
and treatment outcomes.  
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OBJECTIVES: Hypoglycemia symptoms are associated with a high level of fear. 
This study examined the relationships among symptomatic hypoglycemia, fear 
of hypoglycemia, and HRQOL, and focused on whether fear of hypoglycemia is 
independently associated with lower HRQOL. METHODS: Data were collected 
from mail surveys and enrollment information from a sample of adult 
commercial health plan enrollees (n=813) with indentified type-2 diabetes during 
a 12-month period. Patient’s HRQOL was evaluated by the EuroQol (EQ)-5D scale 
and SF-12 scale, and the hypoglycemia fear scale (HFS) was used to assess fear of 
hypoglycemia. We specified two ordinary least square (OLS) models of HRQOL, 
controlling for demographics and illness characteristics. We compared the 
regression coefficients and statistical inferences from two OLS models: Model 1 
included only one variable of hypoglycemia symptoms; Model 2 included both 
hypoglycemia symptoms and HFS score. RESULTS: Model 1: The hypoglycemia 
symptoms alone were associated with worse HRQOL as measured by SF-12 
mental component summary (MCS) and physical component summary (PCS) 
scores and EQ-5D utility score (all p-values <0.05). Model 2: The variable of 
hypoglycemia symptoms was significantly associated only with SF-12 MCS score. 
In contrast, the HFS total score was significantly associated with all three scores 
of HRQOL. The survey analysis also found that the symptoms of hypoglycemia, 
socioeconomic factors (e.g., Hispanic ethnicity), and longer diabetes duration 
were associated with higher level of hypoglycemia fear, whereas higher income 
level, white race, and treatment without either sulfonylurea or insulin were 
associated with lower hypoglycemia fear (all p-values <0.05). CONCLUSIONS: The 
fear and the experience of symptomatic hypoglycemia were both independently 
associated with lower HRQOL (overall health status, mental and physical health). 
Interventions (e.g., patient education programs) can be designed to address the 
fear of hypoglycemia. Choosing a therapy with a lower propensity for 
hypoglycemia may also positively impact QOL.  
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OBJECTIVES: Patients’ with diabetic neuropathy may or may not show 
symptoms. If its progression is not stopped at the earliest, it may lead to foot 
ulceration and amputation. This study was conducted to assess the role of 
Quantitative Sensory Testing (QST) in detection of diabetic neuropathy. Glycated 
hemoglobin (HbA1c) and age are two of the major risk factors for diabetic 
neuropathy. So, relationship of thermal thresholds was seen with HbA1c as well 
as age. METHODS: This was a retrospective observational study conducted on 
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type 2 diabetic patients above 18 years who underwent QST using computer-
driven Medoc TSA II NeuroSensoryAnalyzer system from a period of October 
2011 to May 2012. The results of QST were compared to those of monofilament 
test. RESULTS: Ninety-nine patients (73 males, 26 females) with an average age 
51.49±11.07 years (range: 18-76 years) were recruited in the study. The sensitivity 
and specificity of QST to determine Warm Sensation Threshold, Cold Sensation 
Threshold, Heat Pain Threshold and Cold Pain Threshold in comparison to 
monofilament test was found to be maximum in case of Warm Sensation 
Threshold (86% and 94.5%, respectively). Cold Sensation Threshold was found to 
be inversely proportional to HbA1c (correlation=-0.0909) as well as age 
(correlation=-0.4395). It was also seen that Cold PainThreshold was inversely 
proportional to age (correlation=-0.2143) and Heat Pain Threshold was directly 
proportional to age (correlation=0.2698). CONCLUSIONS: Taking into 
consideration, the high sensitivity and specificity of quantitative sensory testing 
in case of Warm Sensation Threshold and limitations of our study, we conclude 
that Quantitative Sensory Testing can be of use in detecting diabetic peripheral 
neuropathy if used in proper way.  
 
PDB82  
ASSESSMENT OF PREVALENCE AND TOTAL HEALTH CARE COSTS OF 
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OBJECTIVES: High rates of undiagnosed chronic kidney disease (CKD) in type-2 
diabetics (T2DM) indicate that it may not take priority relative to other 
comorbidities. This study examined the prevalence and costs of stage 3-5 CKD in 
relation to other comorbidities within an insured patient population. METHODS: 
Medical and pharmacy claims and laboratory results from a US commercially-
insured population were used to identify patients aged 18-64 with T2DM from 
2006-2010 (the first observed diagnosis as the index date), continuous follow-up 
for 12 months following the index date, and a serum creatinine finding. 
Comorbid hypertension, dyslipidemia, heart diseases/stroke, eye problems, and 
neuropathy were identified during the post-index period based on diagnosis 
codes. Stage 3-5 CKD was identified by medical claims or laboratory findings 
with glomerular filtration rate <60 mL/min/1.73m2. Annual total health care costs 
were reported at follow-up for the selected comorbidities. Generalized linear 
regression models were used to estimate the incremental costs of a given 
comorbidity. RESULTS: The final study sample included 101,964 T2DM patients 
(47.7% hypertension; 53.5% dyslipidemia; 9.7% heart diseases/stroke; 11.6% eye 
problems; 7.0% neuropathy; 9.2% stage 3-5 CKD). The direct annual total mean 
health care costs were $13,158 for all T2DM patients and were as follows for the 
selected comorbidities: hypertension: $16,676; dyslipidemia: $13,537; heart 
diseases and stroke: $39,987; eye problems: $16,017; neuropathy: $24,563; and 
stage 3-5 CKD: $28,325. After adjustment, the incremental costs of these selected 
comorbidities were $2,650, -$545, $17,752, $587, $6,043, and $7,792, respectively 
(all p<0.01). CONCLUSIONS: Among the commercially insured diabetics, the 
prevalence of CKD is similar to heart diseases/stroke, eye problems and 
neuropathy and had the second highest annual health care costs after heart 
diseases/stroke. The burden associated with moderate to severe CKD indicates 
that it should be considered as much as other comorbidities in the care of T2DM 
patients  
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OBJECTIVES: Self-Measurement of Blood Glucose (SMBG) is an important part  
of good diabetes management. Guidelines suggest frequent SMBG testing (the 
number depending on type of diabetes treatment), but there are also limitations 
in some countries on the maximum number of reimbursed strips per month. 
Each SMBG strip costs approximately 0.5€. Limited information on frequency  
of SMBG exists, although it accounts for a considerable proportion of diabetes 
management costs. METHODS: Data were drawn from the 2012 Adelphi Diabetes 
Disease Specific Programme, a cross-sectional survey involving 374 primary  
care physicians and 256 specialists across Europe. Doctors completed patient 
record forms for 7528 consulting patients, 4839 of whom independently 
completed a self-completion questionnaire. SMBG testing frequency was 
analysed separately for type-1 (T1) and type-2 (T2) diabetics and type of 
treatment (non-insulins, basal-only treatment (BOT), basal-bolus (BB) and other 
insulins). RESULTS: Proportion of patient-reported SMBG, T1 93.7%, T2 BOT 
81.0%,T2 BB 88.7%. Physicians reported similar proportions of patients measuring 
their own glucose (T1 94.8%, T2 BOT 79.8% and T2 BB 90.3%). Physician 
recommended SMBG testing between (mean) 31.5 (T2 non-insulins) and 92.4 (T1) 
tests per month with 48.7 for T2 BOT, 81.0 for T2 BB users. The actual mean 
number of patient-reported SMBG tests per month is between 28.8 (T2 non-
insulins) and 94.1 (T1), with 43.4 for T2 BOT, 83.5 for T2 BB.There is thus high 
consistency between patient and physician responses on proportion of patients 
performing SMBG and frequency of testing per month. CONCLUSIONS: Diabetes 
patients appear to accurately follow the SMBG recommendation from their 
physician. Insulin-treated diabetes is associated with frequent SMBG testing, and 
testing frequency increases with number of daily insulin injections. Treatment 
and technologies that can reduce the need for SMBG without compromising 
overall diabetes management could help to reduce overall diabetes management 
costs.  
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OBJECTIVES: To assess the effect of statins on change in renal functions in 
patients with diabetic kidney disease (DKD). METHODS: Medline, Cochrane 
Central Register of Controlled Trials, SCOPUS, PsycINFO, and Web of Science 
databases were searched using the search terms that included Medical Subject 
Headings (MeSH) terms as well as text words. Randomized controlled (either 
parallel or crossover design) trials (RCTs), or quasi-randomized controlled trials 
of statins compared with placebo, other statins, or other drugs conducted in 
patients with either Type 1 or Type 2 DKD were included. We excluded studies in 
patients with kidney injury due to disease other than diabetes mellitus (such as 
gestational diabetes), patients on dialysis and/or with end-stage renal disease, 
and non-English articles. The primary endpoints were the rate of change in 
estimated Glomerular Filtration Rate (GFR) (ml/min) and the change in urine 
albumin excretion rate (AER) from baseline to follow-up. The quality of the 
studies was assessed using risk of bias assessment tool. RESULTS: The search 
yielded 738 studies of which 12 studies, with 3559 patients aged 18 years or older, 
were included. Statins comprised of atorvastatin (n=2), simvastatin (n=5), 
rosuvastatin (n=2), fluvastatin (n=1), lovastatin (n=1), and pravastatin and 
pitavastatin (n=1). The mean duration of follow-up was 15.75 months. Six of the 
studies were double-blinded. The studies were heterogeneous in design, 
treatment, dose and duration of follow-up. In six studies statins either 
significantly reduced albuminuria or prevented the rise of albuminuria. In five 
studies statin use retarded the deterioration of GFR. Thus, statins showed 
modest beneficial effect on renal functions in patients with DKD. CONCLUSIONS: 
Statins may delay the progression of kidney disease in diabetic patients. 
However, additional studies with larger sample size and longer duration of 
treatment are needed to confirm the beneficial effect of statins in patients with 
DKD.  
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OBJECTIVES: The likelihood of reaching A1C treatment targets using 
monotherapy with antihyperglycemic agents (AHAs) is low in patients (pts) with 
type 2 diabetes (T2DM) and moderately elevated A1C levels. AACE/ACE 
guidelines recommend initiating dual therapy (DT) with AHAs in untreated pts 
with an A1C 7.6 – 9.0%. This analysis was to estimate the proportion of 
treatment-naïve pts with T2DM and an A1C 7.6 – 9% who initiate AHA treatment 
with DT and associated pt-related factors. METHODS: Using GE EMR database, 
pts included had a T2DM diagnosis from 2003 to 2010, ≥1 A1C measurement 7.6 – 
9.0% (first instance = index date), continuous enrollment for ≥12 months before 
and ≥6 months after index date, and no AHA prescriptions in one year prior to 
index date. Pts receiving AHA prescriptions for DT within 30 days of index date 
were considered to have initiated DT at index date. Logistic regression identifies 
factors associated with initiating DT. RESULTS: Of the 30,501 selected pts, 8% 
initiated AHA DT and 36% initiated monotherapy within 30 days of the index 
date. After adjusting for baseline, pts with T2DM and an A1C 7.6 – 9.0% were 
more likely to initiate AHA DT if they had higher A1C (adjusted OR = 1.78 [95% CI: 
1.61, 1.97]). Pts were less likely to be prescribed AHA DT if they were older (per 5-
year OR = 0.95 [0.92, 0.97]), lived in regions outside of the South (ORs ranged from 
0.44 – 0.68 for different regions compared to South), or had chronic renal 
disease/renal failure (OR [95% CI] = 0.46 [0.28, 0.76]). CONCLUSIONS: In summary, 
in a cohort of untreated pts meeting AACE/ACE guideline recommendation for 
initiating DT, the proportion of pts initiating DT (8%) or any AHA regimen (44%) 
was low. More strenuous efforts are needed to address underutilization of AHAs 
and appropriate use of DT.  
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OBJECTIVES: We estimated economic burden associated with emergency 
department (ED) visits and outpatient/ambulatory visits for hypoglycemia for 
year 2005-2009. METHODS: We analyzed the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) and the National Ambulatory Medical Care 
Survey (NAMCS). The NHAMCS has ED and outpatient department (OPD) 
components. The unit cost can be estimated from the Medical Expenditure Panel 
Survey (MEPS) for patients with diabetes (n=1010 in 2005, 1115 in 2006, 1039 in 
2007, 1164 in 2008, 1276 in 2009). The annual costs were estimated by the 
multiplication of the MEPS unit costs and annual NHAMCS and NAMCS health 
care utilization associated with hypoglycemia. We did not estimate the annual 
hospitalization costs in NHAMCS OPD and the NAMCS due to no information on 
length of stay. All costs were adjusted to the U.S. 2009 dollars. RESULTS: The 
MEPS unit cost increased from $692 in 2005 to $932 in 2009, the annual 
expenditure of hypoglycemia ED visits fluctuated between $339 million in 2007 
and $400 million in 2006 due to the estimated total hypoglycemia visits declined 
over those 5 years. Hospital admissions from emergency department associated 
